Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147969 | 0.96 | GRIN1 (0.74) | GRIN1GRIN2BGAANPC1RAB9A | |
| Bendazol SCHEMBL309393 | 0.85 | GAA (1.00) | GRIN1GRIN2BGAANPC1RAB9A | |
| Bendazol SCHEMBL29539948 | 0.85 | GAA (1.00) | GRIN1GRIN2BGAANPC1RAB9A | |
| SCHEMBL8640793 | 0.85 | NPC1 (0.65) | GRIN1GRIN2BGAANPC1RAB9A | |
| SCHEMBL7510229 | 0.84 | GRIN1 (1.00) | GRIN1GRIN2BGAANPC1RAB9A | |
| Bendazol SCHEMBL15015931 | 0.83 | GAA (0.96) | GRIN1GRIN2BGAANPC1RAB9A | |
| Bendazol SCHEMBL27823120 | 0.83 | GAA (0.96) | GRIN1GRIN2BGAANPC1RAB9A | |
| SCHEMBL8641196 | 0.82 | GRIN1 (0.63) | GRIN1GRIN2BGAANPC1RAB9A | |
| SCHEMBL11819475 | 0.81 | GRIN1 (0.74) | GRIN1GRIN2BGAANPC1RAB9A | |
| SCHEMBL2241896 | 0.81 | RAB9A (1.00) | GAANPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | CELLTECH THERAPEUTICS LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6319922-B1 | ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | ITGA1, ITGB1, VCAM1 | GRIN1 558/4885GRIN2B 957/4885GAA 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.